Seres Therapeutics (NASDAQ:MCRB) Issues Earnings Results

Seres Therapeutics (NASDAQ:MCRB) posted its quarterly earnings results on Wednesday. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.18) by $2.65, FiscalAI reports. The firm had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.18 million.

Seres Therapeutics Price Performance

MCRB traded down $0.19 on Thursday, reaching $4.82. The company’s stock had a trading volume of 80,159 shares, compared to its average volume of 72,053. The stock has a market cap of $46.66 million, a price-to-earnings ratio of -0.93 and a beta of 0.20. Seres Therapeutics has a 1 year low of $4.59 and a 1 year high of $29.98. The business’s 50 day moving average is $6.29 and its 200 day moving average is $8.55.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. HC Wainwright initiated coverage on Seres Therapeutics in a report on Tuesday, June 23rd. They set a “buy” rating and a $12.00 target price on the stock. Zacks Research upgraded Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. Finally, Weiss Ratings downgraded shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $17.00.

Institutional Investors Weigh In On Seres Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. OMERS ADMINISTRATION Corp acquired a new stake in Seres Therapeutics in the fourth quarter valued at $214,000. State Street Corp grew its holdings in Seres Therapeutics by 14.0% during the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after acquiring an additional 4,170 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of Seres Therapeutics by 4.8% in the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after purchasing an additional 4,723 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Seres Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock valued at $1,282,000 after purchasing an additional 1,160 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Seres Therapeutics in the 3rd quarter valued at about $557,000. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.